The p53 tumor suppressor protein induces apoptosis through a mechanism that may involve the transcriptional activation of cellular genes, including the PIG3 gene. A p53 protein lacking the proline-rich region (p53D62-91) induces many p53-responsive genes but not PIG3. In parallel, this mutant induces growth arrest but not apoptosis. We show here that the replacement of the N-terminal (amino acids 1 ± 80) or C-terminal (amino acids 344 ± 393) domains of p53 with heterologous domains does not interfere with transcription from the PIG3 promoter, but these chimeras still require the proline-rich region for PIG3 activation. The p53-homolog p73b also activated the PIG3 promoter, but in contrast to p53, the proline-rich domain of p73b (residues 81 ± 113) was dispensable to induce the PIG3 promoter. Some tumor-derived p53-mutants, especially M246I, retained the ability to activate transcription of mdm2 but speci®cally failed to induce the PIG3 promoter, thus resembling p53D62-91. Further, p53D62-91 and p53M246I were defective for induction of apoptosis. Finally, p53D62-91 and p53M246I both showed reduced binding to the DNA of the PIG3 promoter and also to the DNA of the mdm2 and p21 promoters in vitro. Correspondingly, at low expression levels, p53D62-91 and p53M246I poorly activated the mdm2 promoter when compared to wild type p53. Our results suggest that the proline-rich domain of p53 aects the ability of the central domain to bind DNA. Moreover, some tumor-derived mutations within the central DNA binding domain of p53 mimic the loss of the proline-rich domain.
Introduction
The p53 protein functions as a tumor suppressor and a regulator of transcription. The p53 gene is the single most commonly mutated gene in tumor material, with alterations found in more than 50% of all human malignancies. In response to DNA damage, the half life of p53 is increased, leading to a net accumulation of the protein within the cell (Levine, 1997) . Intracellular accumulation of p53 can aect the cell in two major ways: Either, the cell is hindered in its further progression through the cell cycle and enters a quiescent state, or apoptotic cell death is induced. At present, the factors that determine the choice between these two possible outcomes are not fully characterized. The decision may depend on the sheer amount of intracellular p53, larger amounts increasing the tendency to apoptosis. Alternatively, posttranslational modi®cations and the conformational state of p53 may in¯uence the decision, as well as the presence of cellular regulatory factors other than p53 (`accessory factors'). Another unsolved problem is the precise mechanism that leads from p53 accumulation to cell death. Since p53 is known to bind speci®c DNA elements and activate transcription from certain promoters, it is an intriguing possibility that the expression of some p53-responsive genes may induce apoptosis. An attractive model for p53-mediated apoptosis was proposed based on the ®nding that a number of p53-responsive genes (so-called p53-induced genes, or PIGs) encode factors that induce the intracellular accumulation of reactive oxygen species (ROS). The accumulation of ROS, in turn, may then induce cell death (Polyak et al., 1997) .
The p53-protein can be divided into distinct functional domains (Harris, 1996) . The N-terminal portion (amino acids 1 ± 61) binds to components of the basal transcriptional machinery and activates transcription. The central domain (amino acids 92 ± 293) interacts directly with promoter-DNA. The Cterminal portion of p53 (amino acids 294 ± 393) is responsible for the tetramer formation of p53 molecules. In addition, it contains regulatory elements that aect DNA binding. The N-terminal and the Cterminal portion of p53 are both subject to posttranslational modi®cations, e.g. phosphorylation (Meek, 1998) and acetylation (Gu and Roeder, 1997) , some of which aect DNA binding and/or the eciency of transactivation. In contrast, no such modi®cations have been reported for the DNA binding domain. In addition to these domains, a portion of p53 between the transactivating domain and the DNA binding domain (amino acids 62 ± 91) was de®ned as the`proline-rich domain' based on the high frequency of proline residues in this portion. It is currently unknown if this domain carries out any independent function. However, based on the frequent proline-X-Xproline motifs within this region, it was proposed that it might be interacting with proteins that contain SH3 domains. The SH3 motif is frequently found in signaltransducing factors (Ruaro et al., 1997; Sakamuro et al., 1997; Walker and Levine, 1996) .
Recently, it was found that mammalian cells contain gene products that are strongly homologous but not identical to p53 and that stimulate transcription from most, if not all, p53-responsive promoters . The ®rst of these p53-homologs to be identi®ed was termed p73 (Kaghad et al., 1997) . One of several alternatively spliced forms of p73, termed p73b, is known to activate transcription from some p53-responsive promoters with equal or greater eciency as compared with p53 (Jost et al., 1997; Kaghad et al., 1997) . p73b also contains a proline-rich region in a position analogous to p53 (c.f. the sequence alignments shown in (Kaghad et al., 1997; Yang et al., 1998) ).
To investigate the function(s) of the proline-rich region within p53, a mutant p53 protein that lacks these residues (62 ± 91) was previously designed. This protein turned out to induce cell growth arrest but not apoptosis (Sakamuro et al., 1997; Walker and Levine, 1996) . This inability of p53D62-91 to induce apoptosis correlated with a selective defect in transcriptional activation. While p53D62-91 activates the p21 promoter and many other p53-responsive promoters, its ability to activate a transiently transfected PIG3 promoter (Venot et al., 1998) and to activate the expression of endogenous PIG3, PIG6 and PIG11 (Zhu et al., 1999) turned out to be severely reduced. This correlation further supports the previously proposed model that PIGs are mediators of p53-induced apoptosis.
These ®ndings raise several important questions regarding p53-mediated apoptosis. First, it needs to be asked whether some naturally occurring, tumorderived mutants of p53 may mimic the phenotype of p53D62-91. Further, it seems possible that certain posttranslational modi®cations of p53, such as phosphorylation, may shift the speci®city of p53 between promoters speci®c for growth-arrest and those regulating apoptosis. Also, it remains open whether p53-homologs, such as the p73 proteins, are capable of inducing PIG3 and other apoptosis-related promoters and whether they require a proline-rich region to do so. Finally, the question arises what mechanism determines the dierential activation of promoters that respond to wild type p53 only versus those that respond to both wild type p53 and p53D62-91.
We show here that posttranslational modi®cations at the N-or C-terminal domains of p53 do not appear to represent major determinants in the discrimination between the mdm2-promoter and the PIG3 promoter. Rather, the presence of the proline-rich domain of p53 appears to modulate the conformation of the DNA binding domain, in¯uencing its capability to bind DNA. Accordingly, some tumor-derived mutations within the DNA binding domain of p53 result in a phenotype resembling p53D62-91.
Results

Phosphorylation at carboxyterminal residues does not affect PIG3 activation
Phosphorylation of p53 in¯uences DNA binding and transcriptional activity. Therefore, we ®rst asked whether phosphorylation of p53 might dierentially aect mdm2 versus PIG3 promoter activity. To investigate the in¯uence of p53 phosphorylation on PIG3 activation, p53 was mutagenized at the C-terminal domain that is known to aect oligomerization and also DNA binding. Several serine residues within the Cterminal domain are sites of phosphorylation (Meek, 1998) . Such residues were mutated to alanine, thus preventing phosphate addition. Expression plasmids for p53 and the phosphorylation mutants were transiently transfected into H1299 cells (a human p53 7/7 cell line derived from an adenocarcinoma of the lung) along with a reporter plasmid that contained p53-responsive portions of the mdm2 promoter or the PIG3 promoter, each regulating the expression of a luciferase reporter. Twenty-four hours after transfection, luciferase activity was determined, re¯ecting promoter activation by the dierent p53 mutants. As shown in Figure 1 , p53 activated both promoters whereas p53D62-91 induced the mdm2 promoter but not the PIG3 promoter, con®rming previous results (Venot et al., 1998) . Further, the mutations S315A, S376A, the combination of two mutations S376A/S378A, and S392A, were all without signi®cant in¯uence on the ability of p53 to activate both promoters in this assay. On the other hand, these point mutations, when introduced into p53D62-91, did not alter the selective defect of p53D62-91 to activate the PIG3 promoter. Finally, deleting the last 30 amino acids of p53 (resulting in a mutant termed p53D30 (Hupp et al., 1992; Jayaraman et al., 1997) ), a region known to be subject to phosphorylation (Meek, 1998) and acetylation (Gu and Roeder, 1997) , enhanced the transcriptional activation of both promoters, but the proline-rich region was still required to activate the PIG3 promoter in this background. Thus, modi®cations of the carboxyterminal domain of p53 do not seem to aect the ability of p53 to activate the PIG3 promoter, nor do they eliminate the need for the proline-rich region of p53 to induce PIG3 transcription.
p53-chimeras with heterologous N-terminal and C-terminal domains activate the PIG3 promoter but still require the proline-rich domain to do so Within p53, only the N-terminal and C-terminal regions have been reported to be modi®ed by Figure 1 Activation of the mdm2 and PIG3 promoters by phosphorylation mutants of p53. H1299 cells were transfected with expression plasmids (vector: pRcCMV, Invitrogen) for p53 and the indicated mutants of it (100 ng), along with a reporter plasmid expressing luciferase under the control of the mdm2 promoter (®lled bars) or the PIG3 promoter (open bars). Twentyfour hours after transfection, luciferase activities were determined. The luciferase activity obtained with wild type p53 was set at 100% in both cases and the other values were normalized accordingly. The average of at least three independent experiments is shown along with the standard error posttranslational modi®cations. In a more rigorous approach to determine the role of these regions in PIG3 activation, we used constructs expressing chimeras of p53 (kindly provided by J Pietenpol and B Vogelstein) (Pietenpol et al., 1994) . In one of these chimeras, the N-terminal transactivating domain of p53 (amino acids 1 ± 80) has been replaced by the transactivating domain of the VP16 protein of herpes simplex virus to create VP16-p53. In another construct, the C-terminal portion of p53 (amino acids 344 ± 393) was replaced by the coiled-coil (CC) domain of the yeast GCN4 protein that mediates oligomerization (Ellenberger et al., 1992; Hu et al., 1990) , yielding a protein termed p53-CC. Both chimeras activated transcription from the mdm2 promoter, as shown in Figure 2 and reported previously (Pietenpol et al., 1994) , and both retained the ability to activate the PIG3 promoter with an eciency comparable to wild type p53. Expression constructs were made to delete the proline-rich region of p53. In the case of VP16-p53, residues 61 ± 79 had already been removed, and in the new construct VP16-p53D62-91, residues 80 ± 91 were deleted in addition; also, residues 62 ± 91 were deleted from p53-CC to create p53D62-91-CC. In both chimeras, deletion of the proline-rich region did not signi®cantly aect the ability to induce the mdm2-promoter but resulted in a complete defect for the induction of the PIG3-promoter. Thus, the proline-rich region of p53 does not seem to carry out its function by a speci®c eect on the N-terminal or C-terminal portion of the protein.
The p53-homolog p73b activates the PIG3 promoter even in the absence of its proline-rich domain 81 ± 113
The p73b protein has been shown to activate several p53-dependent promoters with eciencies comparable to p53 itself (Jost et al., 1997; Kaghad et al., 1997; Zhu et al., 1998) . As shown in Figure 3 , p73b also activates the PIG3 promoter. A proline-rich region including eight proline residues and two PXXP motifs can be found within p73b at a position analogous to p53 (compare sequence alignments shown in Kaghad et al., 1997; Yang et al., 1998) . The amino acid sequence of the proline-rich region within p53 is 62-EAPRM-PEAAP PV APAPAAPTPAAP APAPSWPLSS SVPSQ-100, and the corresponding sequence of p73 is 74-QMSSRAAS ASPYTPEHAASVPTHSPYAQPSSTFD-TMSPAPVIP-116. To learn about the role of this region in the activation of the PIG3 promoter by p73b, residues 81 ± 113 were deleted from p73b. Surprisingly, p73b with this deletion still activated both the mdm2 and the PIG3 promoter. Thus, there is apparently no general need for a proline-rich region between the activation domain and the DNA binding domain of this p53-like protein to activate the PIG3 promoter. When the proline-rich region of p73b (residues 72 ± 117) was used to replace the proline-rich region of p53 (residues 62 ± 91), the resulting chimera still stimulated the mdm2 promoter but not the PIG3-promoter, further arguing that the proline-rich domain of p73b does not perform a function analogous to the corresponding domain within p53.
Since p73b activates the PIG3 promoter even in the absence of a proline-rich domain between the Nterminal and central domains, we speculated that changes within the DNA-binding domain of p53D62-91 may allow it to induce PIG3 transcription without requiring the proline-rich domain. Several single amino acid substitutions within the central DNA binding domain, namely T123P, N239Y, N268D (Brachmann et al., 1998; Nikolova et al., 1998) , were previously shown to enhance the eciency by which wild type and/or mutant p53 binds to its cognate DNA elements. Such point mutations were introduced into p53D62-91. One of the mutations, N239Y, was able to partially, albeit weakly, rescue PIG3 activation when placed into the background of p53D62-91 (data not shown). Thus, it seems that alterations in the DNA binding domain that stabilize the p53-DNA-interaction may at least partially obviate the need for a proline-rich region to induce transcription from the PIG3 promoter.
p53D62-91 inhibits PIG3 activation in a dominant manner
The most commonly studied mutants of p53, such as R273H or R175H, can inhibit the transcriptional activities of wild type p53 in a trans dominant manner, possibly through the formation of hetero-oligomers containing wild type and mutant p53 molecules (Unger et al., 1993) . To test whether p53D62-91 behaves similarly with respect to PIG3 activation, we overexpressed p53D62-91 along with wild type p53, cotransfecting p53-responsive reporter constructs. As shown in Figure 4 , p53D62-91 inhibited PIG3 promoter Figure 2 Activation of the mdm2 and PIG3 promoters by chimeras of p53. Experiments were carried out as described in the legend to Figure 1 except that 500 ng of p53 expression plasmids were used and the backbone vector was pCep4 (Invitrogen) Figure 3 Activation of the mdm2 and PIG3 promoters by p73b. Experiments were carried out as described in the legend to Figure  1 , using p53 and p73b expression plasmids as indicated p53 mutants resembling p53D62-91 J Roth et al activation by wild type p53. Thus, p53D62-91 not only fails to activate the PIG3 promoter but also keeps wild type p53 from doing so. Possibly, this inhibition occurs through the formation of hetero-oligomers incapable of binding PIG3 promoter DNA.
Some tumor-derived p53-mutations within the DNA binding domain cause specific failure to activate the PIG3 promoter
Even though the analysis of the mutant p53D62-91 has led to new insights into the function of p53, the question remains whether p53-mutants similar to p53D62-91 may also arise in nature, i.e. when a malignant tumor develops. Few natural variants of p53 with mutations of the prolines between residues 62 and 91 have been isolated from patient material so far. The substitution P72R is found as a genetic polymorphism, and the question whether it might be correlated with the risk of cervical cancer is currently under discussion (Minaguchi et al., 1998; Rosenthal et al., 1998; Storey et al., 1998; Thomas et al., 1999) . The mutation P82I is found in a cancer-prone family (Sun et al., 1996) , raising the speculation that it might impair the function of the proline-rich region (Sakamuro et al., 1997). Finally, the mutant P85S was isolated from a bladder carcinoma (Taylor et al., 1996) . When these p53-mutants were tested for mdm2 and PIG3 promoter activation, they all induced transcription to a similar extent as wild type p53 ( Figure 5 ), arguing that none of these single substitutions of proline residues abolishes the function of the prolinerich region.
The results obtained with p73b, as well as the partial rescue of PIG3 activation by p53D62-91 through an additional mutation within the DNA binding domain, suggest that the function of the proline-rich region is closely linked to the central domain's DNA binding activity. Therefore, we asked whether tumor-derived mutations within the central domain might selectively aect the ability of p53 to activate the PIG3 promoter. Several mutants of p53 that retain some transcriptional activity have been described in the literature, among them the mutants R175P (Ryan and Vousden, 1998) and M246I (Brachmann et al., 1998 ). These mutants were tested for their activities on the mdm2 and PIG3 promoters ( Figure 5 ). While these mutants showed signi®cant activation of the mdm2 promoter, their ability to induce PIG3 transcription was impaired (R175P) or almost completely abolished (M246I). When assayed in S. cerevisiae, the additional substitution T123P rescued the defective activity of p53M246I (Brachmann et al., 1998) . As shown in Figure 5 , the double mutant p53T123P/M246I also had regained much of the ability to activate the PIG3 promoter. From these experiments, it appears that tumor-derived mutations within the central DNA binding domain of p53 can closely mimic the characteristics of p53D62-91.
The p53-mutant M246I, like p53D62-91, has reduced ability to repress transient reporter expression from the RSV-3'LTR It was previously reported that wild type p53 represses a variety of cotransfected promoters within reporter constructs, such as the Rous sarcoma virus 3' long terminal repeat (RSV-3'LTR) (Jackson et al., 1993) . On the other hand, p53D62-91 reportedly fails to do so (Venot et al., 1998) . To test the ability of tumorderived p53-mutants to confer RSV-LTR promoter repression, a reporter construct with the RSV-3'LTR regulating luciferase expression was cotransfected along with p53 expression constructs, followed by a luciferase assay. As shown in Figure 6 , the tumor-derived mutants p53M246I and p53R175P, as well as p53D62-91, are impaired in their ability to repress this promoter, extending the similarities between these mutants and p53D62-91.
The p53-mutant M246I, like p53D62-91, fails to induce apoptosis To further evaluate the features common to p53D62-91 and the tumor-derived mutant p53M246I, their abilities to induce apoptosis were assessed. H1299 cells were transiently transfected to express wild type p53 and the two p53-mutants. After 72 h, the cells were immunostained for p53 expression, and simultaneously, cells undergoing apoptosis were stained by DNA end labeling (TUNEL assay). As shown in Figure 7 , only 
In contrast, both p53D62-91 and p53M246I failed to do so. The failure of p53D62-91 (Sakamuro et al., 1997) and p53M246I (Brachmann et al., 1998) to induce apoptosis was previously reported in dierent assay systems. Our observation that p53D62-91 and p53M246I lack this activity in parallel experiments further argues that the tumor-derived mutant p53M246I mimics the phenotype of p53D62-91.
The p53-mutant M246I, like p53D62-91, binds poorly to DNA To test the DNA binding properties of p53D62-91 and p53M246I, electrophoretic mobility shift assays (EMSA) were performed. Wild type p53 and the mutants under study were prepared by transcription/ translation in vitro (without adding radioactive label). Equal amounts of the lysates were analysed by SDS ± PAGE and Western blot with antibodies against p53 to show that comparable amounts of the dierent p53 mutants were made (Figure 8a) . These preparations were then incubated with radiolabeled double stranded DNA probes derived from the p53-responsive elements of the mdm2 promoter, the p21/cip1/waf1 promoter and the PIG3 promoter. The oligonucleotides were matched to each other in a way that equal amounts of radioactivity were incorporated into equal numbers of oligonucleotide molecules during the labeling reaction, thus allowing direct comparison. Subsequently, the reaction mixtures were separated on a native polyacrylamide gel, followed by autoradiography and quantitation on a digital image generator. The association between the DNA probe and p53 resulted in lowered electrophoretic mobility as compared to the non-bound probe. Wild type p53 as well as p53D62-91 and p53 M246I bound detectable amounts of mdm2 promoter DNA and p21 promoter DNA, but the mutants both showed a weaker binding eciency than wild type p53 (Figure 8b ). The relative binding eciencies were determined by quantitating band intensities, revealing that the ratio of bound DNA among p53, p53D62-91 and p53 M246I was roughly 16 : 4 : 1 in the absence of antibody 421 (Figure 8b and data not shown). Upon addition of the monoclonal Figure 6 Transcriptional repression by p53 and mutants. A reporter plasmid (1.3 mg) containing the Rous sarcoma virus (RSV) 3' long terminal repeat as a promoter regulating the expression of luciferase was transfected into H1299 cells along with expression plasmids for p53 and the indicated mutants. Luciferase activity was determined 24 h later. In a control experiment (®rst lane), the p53 expression plasmid was replaced by the corresponding empty vector. This value was set at 100% and the other values were normalized accordingly Figure 7 Induction of apoptosis by p53 and mutants. H1299 cells were transfected with expression plasmids (1.3 mg) for p53 and mutants as indicated. Seventy-two hours after transfection, the cells were stained with a TUNEL assay to detect DNA fragments indicative for apoptosis. Simultaneously, p53 was detected by immuno¯uorescence. The cells staining positive for p53 and DNA fragments were counted, and this number was devided by all cells staining positive for p53. The resulting percentage is shown as bars along with the standard error obtained after evaluating three independent experiments (a) Equal amounts of reticulocyte lysate containing p53 and mutants were subjected to SDS gel electrophoresis and Western blotting, followed by detection of p53 using the monoclonal antibody 1801 (Calbiochem). (b) Equal amounts of reticulocyte lysate containing p53 or mutants were incubated with probe DNA. Double-stranded DNA probes were constructed corresponding to the mdm2, p21 and PIG3 promoters, and labeled radioactively. Complexes consisting of DNA and p53 that formed during incubation were separated from free DNA by native gel electrophoresis (free DNA was allowed to run out of the gel). The monoclonal antibody 421 (Calbiochem) directed against p53 was added as indicated. Note that a longer exposure (approximately 25 times longer) is shown when PIG3 promoter DNA was analysed. The positions of complexes consisting of p53 and DNA, or p53 and DNA and antibody, are indicated on the left. An additional band that was consistently observed on longer exposures is marked by an asterisk on the right p53 mutants resembling p53D62-91 J Roth et al antibody 421 to the reaction mix, the bands were supershifted and the binding eciency was enhanced, as reported previously (Hupp et al., 1992) . The relative binding eciencies among p53, p53D62-91 and p53 M246I were roughly 5 : 1 : 1 in this case (Figure 8b and data not shown). Similar ratios were obtained with mdm2 and p21 promoter DNA. When the same experiments were carried out with DNA derived from the PIG3 promoter, binding eciency was generally much weaker than with mdm2 and p21 promoter DNA. (A 25-fold longer exposure is shown in Figure  8b for PIG3 promoter DNA as compared to mdm2 and p21 promoter DNA). However, p53 again bound PIG3 DNA with greater eciency than the two mutants. Thus, it appears that (i) the p53 mutants under study bind the DNA of all three promoters more weakly than wild type p53 and (ii) PIG3 promoter DNA interacts with p53 and its mutants more weakly than mdm2 and p21 promoter DNA. Further, this set of data again strengthens the analogy between the arti®cially generated mutant p53D62-91 and the tumorderived mutant p53M246I.
Low levels of p53 but not p53D62-91 or p53M246I are sufficient for full p21 promoter activation
Since the p53-mutants p53D62-91 and p53M246I generally bind more weakly to promoter-DNA than wild type p53, and since PIG3-promoter-DNA generally interacts more weakly with p53 and its mutants than mdm2-promoter DNA, it can be expected (and can be observed in Figure 8 ) that these two eects add up and render the interaction of p53D62-91 and p53M246I with the PIG3-promoter DNA particularly weak. In this case, the resulting binding eciency may fall below a threshold required for promoter activation (see Discussion), thus leading to the selective defect of p53D62-91 and p53M246I in the activation of the PIG3 promoter. To further evaluate this`threshold hypothesis', we tested how the promoters under study respond to low amounts of p53 (either wild type or mutants).
To this end, we performed a titration experiment by transfecting various amounts of p53 expression plasmids (p53, p53D62-91 and p53M246I) along with the p53-responsive reporter plasmids (mdm2-promoter and PIG3 promoter). Luciferase activities were plotted against the amounts of p53 expression plasmids, as shown in Figure 9 . Two observations were made: (i) The mdm2 promoter was activated even by very low amounts of wild type p53, whereas considerably higher amounts of expression plasmids were needed when using p53D62-91 and p53M246I to obtain comparable luciferase activities; (ii) For maximum activation, the PIG3 promoter required more wild type p53 than the mdm2 promoter.
Discussion
Our results show that the proline-rich region of p53 cooperates with the DNA binding domain to interact with the PIG3 promoter DNA and to activate transcription. This happens independently of the Nterminal and C-terminal domains. p73b activates the PIG3 promoter even when the homologous proline-rich domain is deleted, and a suitable mutation within the central domain of p53 compensates to some extent for the deletion of the proline-rich domain within p53. This argues that the proline-rich domain of p53 does not carry out an evolutionary conserved, autonomous function but rather has an auxiliary eect on the interaction between the central domain and the DNA. Some mutations within the central region of p53 (e.g. p53M246I) result in a phenotype that is almost indistinguishable from p53D62-91, further supporting this hypothesis. Also, mutations like M246I do arise in malignant tumors, strongly suggesting that the phenotype of p53D62-91 and p53M246I is physiologically relevant in oncogenesis. In a previous report, p53 and p53D62-91 were shown to bind PIG3 promoter DNA with dierent eciencies only when produced in mammalian cells but not when puri®ed from baculovirus-infected insect cells. Further, no signi®cant dierence was reported in binding eciency of p53 and p53D62-91 to the p21 promoter DNA (Venot et al., 1998) . In contrast, our results reveal that p53D62-91 and p53M246I bind to PIG3 promoter DNA and mdm2 promoter DNA, as well as p21 promoter DNA, with lower eciencies than wild type p53. The apparent discrepancy may be due to the fact that higher amounts of p53 were used in the previous study. Thus, only an excess of p53D62-91 may bind p21 promoter DNA with an eciency comparable to wild type p53.
If p53D62-91 and p53M246I generally bind DNA with lower eciency in vitro, why do they show a selective defect in activation of the PIG3 promoter A B Figure 9 Promoter activation by low amounts of p53, p53D62-91 and p53M246I. Expression plasmids for p53, p53D62-91 and p53M246I were transfected in dierent amounts as indicated (ng), along with reporter plasmids containing the mdm2 promoter (a) or the PIG3 promoter (b). Twenty-four hours after transfection, luciferase activities were determined (arbitrary units) but not the mdm2 promoter in vivo? We initially speculated that the two p53 mutants under study may be expressed to higher levels than wild type p53, thus compensating for decreased binding to the mdm2 promoter. However, at the time of the luciferase assay (24 h after transfection), p53 and its mutants were expressed to equal levels, as determined by Western blot analysis (data not shown). We propose that p53 needs to bind a promoter with an eciency above a certain threshold in order to activate transcription. Binding eciencies further exceeding this threshold would not yield signi®cantly stronger transactivation, but binding eciencies below the threshold would result in a failure to transactivate. According to this model, the interaction eciencies of wild type p53, p53D62-91 and p53M246I with p21 and mdm2 promoter DNA may all exceed this threshold when p53 or mutants are expressed in relatively high amounts, thus resulting in transcriptional activation. At low expression levels, only wild type p53 but not p53D62-91 and p53M246I activates the mdm2 promoter with maximum eciency (Figure 9 ), possibly re¯ecting the lower binding eciency of p53D62-91 and p53M246I to mdm2 promoter DNA. On the other hand, since the PIG3 promoter DNA associates with p53 to a lesser extent than mdm2 promoter DNA, only wild type p53 may be able to bind PIG3 promoter DNA with an eciency above the threshold, while p53D62-91 and p53M246I fail to do so. But even wild type p53 needs to be expressed at relatively high levels to fully activate the PIG3 promoter (Figure 9 ), possibly due to the lower binding eciency of PIG3 promoter DNA to p53. Correspondingly, it has been reported earlier that low levels of p53 induce cell cycle arrest but not apoptosis (Chen et al., 1996) .
Our results strongly suggest that the proline-rich region of p53 enables the central domain to bind PIG3 DNA and other p53-responsive elements with greater eciency. The mechanism for this remains to be determined. Given the presence of PXXP motifs in human (Walker and Levine, 1996) and murine (Sakamuro et al., 1997) p53, it has been proposed that SH3-domains may interact with the proline-rich domain (Ruaro et al., 1997) . We cannot exclude the possibility that the interaction with such a protein aects the conformation of p53, resulting in stronger DNA binding eciency. Proteins that increase the DNA binding activity of p53 include HMG-1 (Jayaraman et al., 1998) and Ref-1 (Jayaraman et al., 1997) , but neither of them was shown to interact directly with p53, and neither was reported to contain an SH3 domain.
A simpler explanation for the function of the proline-rich domain is that it may directly aect the conformation of the central domain within p53 through interaction of the two adjacent protein domains. Such an alteration of its conformation may in turn allow the central domain to bind the PIG3 promoter DNA, and increase binding eciency to other p53 responsive elements. Such a model would also accommodate the result that p53D62-91 inhibits p53-mediated PIG3 promoter activation in a trans dominant manner, since a p53-tetramer requires four functional DNA-binding domains to interact eciently with a cognate DNA element of p53. A ®nal proof for the proline-rich domain in¯uencing the conformation of the central domain can only be provided if the structure of both components will be known. So far, only the central domain separately from other p53-domains has been characterized by the determination of its crystal structure (Cho et al., 1994) . Although this has provided much insight into the p53-DNA-interaction, a complete understanding of DNA binding by p53 can only be provided by the structure of a p53 tetramer.
Why does p73b not require a proline-rich region between the N-terminal and central domains in order to activate the PIG3 promoter? Possibly, the central domain of p73b can bind PIG3 DNA without requiring the auxiliary eect of additional protein regions. Indeed, p73b seems to bind PIG3 DNA more eciently than p53 in electrophoretic mobility shift assays (data not shown). Alternatively, however, it is possible that a second proline-rich domain within p73b eliminates the need for residues 81 ± 113. Accordingly, a proline-rich region within the Cterminal portion of p73 was shown to interact with the c-abl kinase, leading to phosphorylation of p73 and activation of its pro-apoptotic function (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . In contrast, no such C-terminal proline-rich domain is found in p53, and the reported interactions of p53 with c-abl (Sionov et al., 1999) were thus proposed to be of a more indirect nature (White and Prives, 1999) . A recent report (Yu et al., 1999) concluded that p73 was unable to activate the PIG3 promoter. It should be noted, however, that the a form of p73 was used there, whereas the b form was used in our study. Since the b form is apparently a more ecient transactivator than p73a (Roth et al., 1998) , this provides a plausible explanation for the apparent discrepancy.
It is presently unknown why the proline-rich domain is rarely, if at all, mutated in tumors. The fact that some tumor-derived mutations within the central domain closely resemble p53D62-91 in their phenotype further raises the question why tumors almost exclusively evolve to mutate the central domain of p53. Possibly, single amino acid changes are generally insucient to abolish the proline-rich region's function, as suggested by the mutants analysed in this study. The deletion of larger regions, on the other hand, may be less likely to occur when compared to point mutations.
Finally, the question arises why some tumors select for p53 mutations, such as p53M246I or p53R175P, that do not entirely abolish the function of p53. We propose that the cell cycle arrest function that is re¯ected by the ability to induce the p21 and mdm2 promoters may be bene®cial to tumor growth under some circumstances. If a tumor cell divides without any p53-mediated growth control, damage to the DNA may be so severe that the cell does not survive. If, on the other hand, p53 halts cell growth to allow proper DNA repair, this may be of advantage for the tumor cells in the long-term. While the apoptosis-inducing function of p53 apparently can prevent tumor growth, the cell cycle arrest function may contribute to the survival of tumor cells, leading to the selection of p53-mutants that contain a partial, p53D62-91-like functional defect.
Materials and methods
Plasmid construction
All p53-mutants were created by oligonucleotide-directed mutagenesis (Quikchange, Stratagene). To make single amino acid changes, the corresponding codon was exchanged. For larger deletions, oligonucleotides were designed to`bridge' the coding regions for the residues to be deleted. To create the chimera p53inp73, a ClaI site was introduced into the coding region of p53, replacing the coding region for residues 61 ± 92, using the mutagenesis primer CTGAAGACCCAGG-TATCGATTCTGTCCCTTCCCAG and a primer of complementary sequence. Subsequently, a portion of the p73 coding region was PCR-ampli®ed with the primers GCCA-TCGATAAGCTTATGGACCAGATGAGCAGCCGC and GCCATCGATGGAGGGGATGACAGGCGCCGG. The PCR-fragment was then cloned into the modi®ed p53 coding region using ClaI. The plasmids were con®rmed by sequencing.
A reporter construct for the PIG3 promoter was constructed by cloning a 0.7 kb HindIII-SspI-fragment of the PIG3 promoter region (taken from the plasmid pBR322pl-LUC-pig3-del-prom, generous gift of B Vogelstein) into the vector pGL3Basic (Promega) cut with the restriction enzymes HindIII and SmaI. The resulting reporter plasmid yielded higher amounts of luciferase when compared to pBR322pl-LUC-pig3-del-prom (data not shown). A reporter construct with a fragment of the mdm2 promoter inducing luciferase expression (pBP100luc) was described previously (Freedman et al., 1997) . To make a construct with the Rous sarcoma virus (RSV) 3' long terminal repeat directing luciferase expression, the RSV promoter DNA was isolated from pRep4 (Invitrogen) using SalI and HindIII, and ligated into the vector pGL3Basic (Promega) that was ®rst treated with XhoI and HindIII.
To generate p53 and its mutants by in vitro transcription and translation, a plasmid containing the coding region of p53 in the vector pOS7 was used (generous gift by N Horikoshi, Boston). This vector contains a T7 phage RNA polymerase promoter, followed by an internal ribosomal entry site and the p53 coding region. Mutants of p53 were created in this vector by site-directed mutagenesis as outlined above.
Cell culture and transfections
H1299 cells were maintained in Dulbecco's modi®ed eagle media supplemented with 10% fetal calf serum. For transfections, 2610 5 cells were seeded on each well (3.5 cm in diameter) of a six-well dish (Nunc) and transfected with 1.5 mg (total) of plasmid DNA using 5 ml of FuGene6 (Roche) according to the manufacturer's instructions. Cells were harvested 24 h after transfection and subjected to luciferase assays (Promega).
Assay for apoptosis H1299 cells were seeded on chamber slides (Nunc) and transfected as described above. Seventy-two hours after transfection, the cells were ®xed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100, each in PBS. The cells were then immunostained for p53 as described previously (KoÈ nig et al., 1999) , using a Texas Red ± labeled secondary antibody. Simultaneously, the free DNA ends that typically occur during apoptosis were labeled with FITC as described (TUNEL assay, (Dobbelstein and Shenk, 1996) ). The percentage of TUNEL-positive (i.e. apoptotic) cells among the p53-expressing cells was calculated in each case.
Electrophoretic mobility shift assay (EMSA) p53 and its mutants were generated by in vitro transcription and translation using T7 RNA polymerase and rabbit reticulocyte lysate (Promega). These preparations (2.5 ml) were incubated with 1 ml sheared salmon sperm DNA (0.1 mg/ml), 1 ml poly dAdT (1 mg/ml), and 7 ml EMSA buer (25 mM Tris-Cl pH 7.5, 130 mM NaCl, 3 mM KCl, 5% bovine serum albumine, 12% glycerol, 1 mM dithiothreitol) for 10 min at 238C. Subsequently, 2 ng of the radiolabeled DNA probe was added. (The probes were generated by annealing the appropriate oligonucleotides to each other and performing a ®ll-in reaction including a-32 P-dCTP.) The incubation was then continued for 1 h at room temperature. The reaction mixes were separated at 48C on a native 5% polyacrylamide gel with 0.5 TBE as running buer. The radiolabeled oligonucleotides were then detected by autoradiography using a Bioimager (Fuji). The oligonucleotides used to generate the probes had the following sequences: mdm2-probe: GATCGCGGCCGCTGGTCAAGTTGGGA-CA and GGGCCGGACGTGTCCCAACTTGACCAGCG-GCCGC; p21-probe: GATCGCGGCCGCGAACATGTCC-CAACA and GGGCAACATGTTGGGACATGTTCGCG-GCCGC; PIG3-probe: GATCGCGGCCGCCAGCTTGCC-CACCCA and GGGGAGCATGGGTGGGCAAGCTGGC-GGCCGC.
